Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Buy" by Analysts

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) has earned an average rating of "Buy" from the fourteen ratings firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $87.15.

A number of brokerages recently commented on VKTX. B. Riley reaffirmed a "buy" rating and issued a $96.00 target price (down from $109.00) on shares of Viking Therapeutics in a research report on Friday, February 7th. HC Wainwright restated a "buy" rating and set a $102.00 price objective on shares of Viking Therapeutics in a report on Thursday, April 24th. Piper Sandler lowered their target price on Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating on the stock in a research report on Thursday, February 6th. Truist Financial reissued a "buy" rating and issued a $75.00 price target (down previously from $95.00) on shares of Viking Therapeutics in a research report on Monday, April 28th. Finally, Citigroup initiated coverage on shares of Viking Therapeutics in a report on Friday, February 7th. They set a "neutral" rating and a $38.00 price objective on the stock.

Insider Activity at Viking Therapeutics

In other Viking Therapeutics news, Director Sarah Kathryn Rouan purchased 1,240 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was bought at an average cost of $24.15 per share, with a total value of $29,946.00. Following the completion of the transaction, the director now owns 1,240 shares of the company's stock, valued at $29,946. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 4.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Blue Trust Inc. raised its stake in shares of Viking Therapeutics by 75.9% during the 4th quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 309 shares during the period. Quarry LP increased its holdings in Viking Therapeutics by 1,621.4% during the first quarter. Quarry LP now owns 1,205 shares of the biotechnology company's stock worth $29,000 after buying an additional 1,135 shares during the last quarter. YANKCOM Partnership bought a new stake in Viking Therapeutics in the fourth quarter worth about $33,000. Parallel Advisors LLC boosted its stake in Viking Therapeutics by 64.8% in the first quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 536 shares during the last quarter. Finally, FIL Ltd grew its position in shares of Viking Therapeutics by 116.8% during the 4th quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 648 shares during the period. Institutional investors own 76.03% of the company's stock.

Viking Therapeutics Stock Up 0.1%

NASDAQ:VKTX opened at $27.04 on Friday. Viking Therapeutics has a twelve month low of $18.92 and a twelve month high of $81.73. The company has a fifty day moving average of $25.85 and a 200-day moving average of $33.17. The firm has a market capitalization of $3.04 billion, a P/E ratio of -27.04 and a beta of 0.75.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). During the same quarter in the previous year, the company earned ($0.26) EPS. The firm's revenue for the quarter was up .0% on a year-over-year basis. On average, analysts anticipate that Viking Therapeutics will post -1.56 EPS for the current fiscal year.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.